Life extension

Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 – Coherent Market Insights

Retrieved on: 
Tuesday, December 17, 2019
General Health, Other Health, Health, Stem cells, Physical therapy, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Emerging technologies, Life extension, Stem-cell therapy

According to Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027).

Key Points: 
  • According to Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027).
  • Key players are focused on launches of production facility for offering better stem cell therapy in the potential market.
  • This acquisition is expected to strengthen Bayers market position in the stem cell therapy market.
  • Global Stem Cell Therapy Market, By Cell Source:

MYOS to Introduce its Longevity Business with its Physician Muscle Health Formula at the World Congress on Anti-Aging Medicine in Las Vegas December 13-15, 2019

Retrieved on: 
Tuesday, December 10, 2019
Demography, Population, Senescence, Longevity, Ageing, Life extension

Considered the largest event in anti-aging medicine, the World Congress is expected to draw approximately 4,000 Medical Professionals and 300 Exhibitors from around the world.

Key Points: 
  • Considered the largest event in anti-aging medicine, the World Congress is expected to draw approximately 4,000 Medical Professionals and 300 Exhibitors from around the world.
  • Encouraged by positive results from this clinical study and previous studies showing that Fortetropin increases muscle mass and strength, MYOS decided to formally launch its longevity business by introducing its branded product, Physician Muscle Health Formula.
  • This product will be distributed through medical practices focused on anti-aging medicine across the United States.
  • "Fortetropin has remarkable potential to improve human longevity and we are pleased to share our advancements on improving muscle health at the upcoming World Congress on Anti-Aging Medicine later this week," commented Joseph Mannello, CEO of MYOS.

Top Florida Medical Spa, Amnion of Florida, Partners With Merakris Therapeutics to Advance Their Non-Surgical Treatment Options

Retrieved on: 
Monday, December 9, 2019
Alternative medicine, Health, Other Health, Transhumanism, Demography, Articles, Rejuvenation, Senescence, Amnion, Life extension, Surgery

Amnion announces a partnership with Merakris Therapeutics, LLC to advance the development of Merakris topical bioactive anti-aging hydrogel technology.

Key Points: 
  • Amnion announces a partnership with Merakris Therapeutics, LLC to advance the development of Merakris topical bioactive anti-aging hydrogel technology.
  • Amnion is focused on attracting women and men seeking affordable non-surgical options for youth maintenance via cell activated procedures, hair restoration, joint repair, dermal rejuvenation, and anti-aging treatments.
  • In a constantly changing field, Amnion of Florida, under the guidance of the on-site medical staff, provides the highest level of quality products and procedures in cosmetic medicine.
  • Merakris Therapeutics, based in Research Triangle Park, North Carolina, is focused on researching, developing, and marketing regenerative healthcare products.

Sharecare wins eight Digital Health Awards in Fall 2019 competition

Retrieved on: 
Tuesday, December 3, 2019
Medical websites, Life extension, Positive psychology, Sharecare, Health, Jeff Arnold

ATLANTA, Dec. 3, 2019 /PRNewswire/ -- Sharecare, the digital health company that helps people manage all their health in one place, today announced it was honored in the Fall 2019 competition of the Digital Health Awards for its platform, as well as its features, interactive tools and engaging multi-platform content.

Key Points: 
  • ATLANTA, Dec. 3, 2019 /PRNewswire/ -- Sharecare, the digital health company that helps people manage all their health in one place, today announced it was honored in the Fall 2019 competition of the Digital Health Awards for its platform, as well as its features, interactive tools and engaging multi-platform content.
  • Hosted by the Health Information Resource Center to recognize the world's best digital health resources for consumers and healthcare professionals, the Digital Health Awards competition is held twice each year spring and fall.
  • With eight wins in the Fall 2019 competition, Sharecare won a total of 18 Digital Health Awards in 2019.
  • The full list of Sharecare's Digital Health Awards in the Fall 2019 competition is as follows:

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions

Retrieved on: 
Tuesday, December 3, 2019
Articles, Branches of biology, Biology, Stem cells, Biotechnology, Cell biology, Life extension, Stem-cell therapy, Cell therapy, Therapy, Outsourcing

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies.
  • Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.
  • As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs).

Health Evolution Announces New Distributor for TeloMind™ YTE® Stem Cell Formula Supplement

Retrieved on: 
Friday, November 22, 2019
Branches of biology, Biology, Life sciences, Life extension, Biotechnology, Cell, In science, Rejuvenation, Stem cell

LAS VEGAS, Nov. 22, 2019 /PRNewswire/ --Health Evolution today announced that its TeloMind stem cell formula is available through new distributors:

Key Points: 
  • LAS VEGAS, Nov. 22, 2019 /PRNewswire/ --Health Evolution today announced that its TeloMind stem cell formula is available through new distributors:
    Health Evolution Project is a wholly owned subsidiary and marketing channel for Health Evolution Products, distributing through a network of Partners throughout the United States and internationally.
  • The keystone product of Health Evolution is TeloMind, a stem cell rejuvenation formula incorporating the proprietary Norwegian YTE (Youth Tissue Extract), which is exclusive to Health Evolution.
  • TeloMindwhich has been wholly-owned and marketed by Health Evolution since 2016is independently tested to verify clinical doses of YTE dynamic Youth Tissue Extract.
  • Angela Wright, Research Coordinator at Health Evolution, says,"Athletes, professionals, and medical specialists already are recommending TeloMind to family, friends, and patients.

BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology

Retrieved on: 
Wednesday, November 20, 2019
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Emerging technologies, Life extension, Stem-cell therapy, Cell therapy, Draft:BrainStorm Cell Therapeutics

The objective of the randomized placebo-controlled Phase 2 clinical trial was to determine the safety and efficacy of a single transplantation of autologous bone-marrow derived MSC-NTF cells (NurOwn) in participants with ALS.

Key Points: 
  • The objective of the randomized placebo-controlled Phase 2 clinical trial was to determine the safety and efficacy of a single transplantation of autologous bone-marrow derived MSC-NTF cells (NurOwn) in participants with ALS.
  • BrainStorms NurOwn cell therapy is the furthest advanced autologous stem cell treatment in development for ALS.
  • On October 11, the Company announced that the NurOwn, Phase 3 clinical trial for ALS was fully enrolled.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Therapeutics Solutions International Signs Agreement With Beijing Regenesis Biotechnology to License and Develop Patent for Anti-aging Use of Cord Blood Plasma and NanoStilbene

Retrieved on: 
Monday, November 11, 2019
Articles, Transhumanism, Academic disciplines, Natural sciences, Blood, Emerging technologies, Life extension, Stem cells, Parabiosis, Rejuvenation, Cord blood, ReGenesis

OCEANSIDE, California, Nov. 11, 2019 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the signing of a Letter of Intent with Beijing Regenesis Biotechnology Co. Ltd., of Beijing China to develop and commercialize the anti-aging properties of cord blood plasma combined with NanoStilbene.

Key Points: 
  • OCEANSIDE, California, Nov. 11, 2019 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the signing of a Letter of Intent with Beijing Regenesis Biotechnology Co. Ltd., of Beijing China to develop and commercialize the anti-aging properties of cord blood plasma combined with NanoStilbene.
  • We have previously commercialized novel technologies for rejuvenation of testicular and ovarian function," said Dr. Fei Li, Chief Executive Officer of Beijing Regenesis.
  • "Cord blood components have been used for more than a Century in medicine with an excellent safety profile.
  • "We are very excited to commercialize the use of cord blood plasma with NanoStilbene as a means of translating the animal parabiosis experiments into humans."

Exosome Procedures Now Being Included With the R3 Stem Cell Regenerative Aesthetics Training Course

Retrieved on: 
Thursday, October 31, 2019
Branches of biology, Biology, Life sciences, Regenerative biomedicine, Emerging technologies, Life extension, Biotechnology, Regenerative medicine, Rejuvenation, Stem cell, Regenerative medicine

SCOTTSDALE, Ariz., Oct. 31, 2019 /PRNewswire-PRWeb/ --R3 Stem Cell, the nation's leader in regenerative medicine training, is now including exosome procedures in its regenerative aesthetics courses.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 31, 2019 /PRNewswire-PRWeb/ --R3 Stem Cell, the nation's leader in regenerative medicine training, is now including exosome procedures in its regenerative aesthetics courses.
  • At the R3 Stem Cell Regenerative Aesthetics Course, providers learn leading techniques for hair restoration, facial rejuvenation and ED.
  • According to R3 CEO David Greene, MD, MBA, " Exosome therapy has been a very exciting addition to regenerative medicine.
  • R3 Stem Cell has first rate trainers who have performed thousands of regenerative cases for hair restoration, facial rejuvenation and sexual health.

Committee to hear evidence on potential treatments to combat ageing

Retrieved on: 
Saturday, October 26, 2019
Old age, Ageing, Gerontology, Demography, Adulthood, Life extension, Immortality

In the first session the Committee will ask what advances are being made in medical treatments that target age-related diseases and the ageing process, in order to tackle the consequences of ageing as a whole.

Key Points: 
  • In the first session the Committee will ask what advances are being made in medical treatments that target age-related diseases and the ageing process, in order to tackle the consequences of ageing as a whole.
  • If treatments that target the whole ageing process (such as senolytics) prove to be promising, how and to whom would they be administered?
  • On the effect of ageing on the immune system, and whether there are adequate funding opportunities for researchers studying the ageing system as whole:
    What is the state of the evidence underlying senolytics drugs to target the processes of ageing?
  • What challenges face the development and trialling of treatments that target the ageing process?